Healthcare perspectives from The Economist Intelligence Unit

Color

#DB444B

Hero Carousel

Spotlight

Bringing healthcare to hard-hit areas in Bangladesh

YouTube

https://www.youtube.com/channel/UCQDMOSbJtqrtNzif5rS22OQ

Slideshare

http://www.slideshare.net/economistintelligenceunit

Pinterest

https://www.pinterest.com/theeiu/

Reopening the ethical debate on genetic engineering

A new technique has made it possible and cheap to edit the human germline. Society needs to discuss the ethical implications sooner rather than later

Cost-efficiencies in healthcare

How Gulf policymakers can get to grips with the growing diabetes challenge

The diabetes burden in the Gulf is rising fast. More and more people develop the disease. In Saudi Arabia, already almost a quarter of the adult population has the disease. Economic costs are set to grow significantly too. More can be done to combat the disease, and our research has identified several underused policy options, including stronger engagement of community leaders, tougher regulation and investment in primary healthcare.

Tuberculosis control in Poland

Tuberculosis control in Poland has been extremely successful in turning a general scourge into one affecting only pockets of the population. If the country's health officials want to go further, however, they will need to find new ways to help socially marginalised groups.

 

Download translation:

Financing the future

Financing the future: Choices and challenges in global health studies the role of healthcare against a backdrop of changing demographic patterns, rising healthcare costs and technological innovation. The briefing paper highlights several effective approaches particular countries have adopted in response to funding challenges, and also shines a light on companies that have implemented programmes supporting their employees.

Rising cost of healthcare a big concern for both private and public sector executives and government’s role is important, new EIU report finds

Le système de santé fondé sur la valeur en France

Value-based healthcare in France

Value-based healthcare in France: A slow adoption of cost-effectiveness criteria

Key findings

  • In France, the level of improvement is a key determinant rather than price in deciding how innovation is valued.
  • Patient access to new drugs is highly valued and influential in how the French healthcare system is organised.
  • A lack of transparency in the way in which final prices for new drugs are negotiated curbs progress of value-based healthcare in France.

From transplants to implants

Will patients welcome the idea of living with artificial organs in their body?

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week